1 week Ago By ABMN Staff
National Bank of Canada FI lowered its position in shares of Moderna, Inc. ( NASDAQ:MRNA – Free Report ) by 26.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The firm owned 144,527 shares of the company’s stock after selling 50,897 shares during the period. National Bank of Canada FI’s holdings in Moderna were worth $16,757,000 at the end of the most recent quarter. Other institutional investors and hedge funds have also recently made changes to their positions in the company.
Ogorek Anthony Joseph NY ADV purchased a new position in Moderna during the 4th quarter valued at about $27,000. Family Firm Inc. purchased a new position in Moderna during the second quarter valued at approximately $33,000.
Cedar Wealth Management LLC raised its stake in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter.
Westside Investment Management Inc. purchased a new stake in Moderna during the first quarter worth $32,000. Finally, Bank & Trust Co purchased a new stake in Moderna during the second quarter worth $36,000.
75.33% of the stock is currently owned by institutional investors. Insider Transactions at Moderna In related news, Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction on Tuesday, June 11th.
The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88.
Following the completion of the transaction, the director now directly owns 1,528,557 shares in the company, valued at $226,746,145.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website .
In related news, Director Noubar Afeyan sold 202,832 shares of Moderna stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.
88. Following the completion of the transaction, the director now directly owns 1,528,557 shares in the company, valued at $226,746,145.38.
The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $138.
16, for a total value of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares in the company, valued at approximately $201,311,416.
24. The disclosure for this sale can be found here . Insiders have sold 316,168 shares of company stock worth $44,094,621 over the last 90 days.
15.70% of the stock is currently owned by company insiders. Moderna Stock Down 0.
7 % Moderna ( NASDAQ:MRNA – Get Free Report ) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.
47) by $0.14. Moderna had a negative return on equity of 21.
35% and a negative net margin of 116.18%. The firm had revenue of $241.
00 million for the quarter, compared to analyst estimates of $128.41 million. During the same quarter in the prior year, the firm earned ($3.
62) earnings per share. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis.
Equities analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current year.
Wall Street Analyst Weigh In Several research firms have recently commented on MRNA. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. Barclays decreased their price target on shares of Moderna from $168.
00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price objective for the stock from $85.
00 to $80.00 in a research report on Wednesday, August 7th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th.
Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Ten investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.
com, the company presently has a consensus rating of “Hold” and an average target price of $123.79. Read Our Latest Analysis on Moderna Moderna Company Profile ( Free Report ) Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Further Reading Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc.
( NASDAQ:MRNA – Free Report ). Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter .
.
